ABAna Rita Brochado

Ana Rita Brochado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ana Rita Brochado has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Human-targeted drugs impact antibiotic sensitivity and growth of Campylobacter jejuni

    by Annamaria Zannoni, Roberto Olayo-Alarcon, Martin K. Amstalden, Medina Feldl, Rebecca Würz, Thea Bruchhardt, Johannes Kullmann, Sarah L. Svensson, Christoph Sotriffer, Mona Alzheimer, et al.

    Antibiotic resistance is increasingly recognized as a major threat to global health, yet the contribution of non-antibiotics to this problem remains poorly defined. Here, we established a transcriptional chemical genomics approach to map how 2,415 host-relevant small molecules influence stress-responsive promoters and fitness of the foodborne pathogen Campylobacter jejuni. This screen uncovered widespread activation of the CmeABC efflux pump by diverse compounds, including several human-targeted drugs. Notably, ibuprofen, one of the most widely used non-steroidal anti-inflammatory drugs worldwide, induced efflux pump expression and thereby enhanced bacterial tolerance to ciprofloxacin. We also identified multiple commensal-sparing human-targeted drugs with growth-inhibitory activity against C. jejuni , highlighting opportunities for pathogen-targeted drug repurposing. Together, our findings reveal that non-antibiotic drugs can both promote resistance-associated phenotypes and selectively suppress pathogen growth. This underscores the need to consider collateral drug effects on bacterial physiology when designing strategies to curb the burden of antimicrobial resistance.

  • Open Access

    Human-targeted drugs extensively reshape regulatory networks controlling virulence and antibiotic resistance in Salmonella Typhimurium

    by Martin K. Amstalden, Roberto Olayo-Alarcón, Susanne Brenzinger, Lorine Debande, Annamaria Zannoni, Elisabetta Fiore, Abdelhakim Boudrioua, Azam Rashidian, Thales Kronenberger, Samuel Wagner, et al.

    Human-targeted drugs are increasingly recognized to affect bacterial physiology, yet their impact beyond growth inhibition, and the underlying molecular mechanisms, remain poorly understood. Here, we systematically mapped how chemically diverse host-associated compounds influence virulence and intrinsic antibiotic resistance in Salmonella enterica serovar Typhimurium. Using a high-throughput reporter approach, we quantified transcriptional response of 26 key stress promoters in Salmonella against 2,415 compounds, including FDA-approved drugs, food-derived molecules, and human metabolites. We found that non-antibiotic compounds induce transcriptional responses distinct from those elicited by antibiotics, uncovering a regulatory shift from general stress responses to compound-specific regulation driven by ligand-responsive MarR- and TetR-family regulators. In particular, more than 200 non-antibiotic drugs modulate virulence or intrinsic resistance pathways through the central regulators SlyA or RamR, respectively. By integrating our large-scale dataset with machine learning, we further defined chemical features associated with ramA transcriptional activation in Salmonella , and predicted ∼200 additional candidate inducers of intrinsic antibiotic resistance in this pathogen. Together, our results uncovered a large and previously unrecognized chemical landscape that reshapes bacterial stress responses through ligand-responsive regulatory mechanisms, with implications for how host-associated compounds influence pathogen virulence and antibiotic resistance. Highlights: Mapping the transcriptional response of key Salmonella stress pathways across a large chemical space shows that antibiotics and non-antibiotic compounds elicit distinct stress responses in Salmonella The activity of the virulence regulator SlyA is modulated by non-antibiotic compounds SlyA-inhibitors increase sensitivity to polymyxin B and decrease Salmonella virulence in cell culture Human-targeted drugs increase intrinsic antibiotic resistance via RamR-RamA in Salmonella Machine learning approach enables large-scale, out-of-sample prediction of human-targeted drugs inducing ramA expression in Salmonella


  • Open Access

    Systematic screen uncovers regulator contributions to chemical cues in Escherichia coli

    by Christoph Binsfeld, Roberto Olayo-Alarcon, Lucía Pérez Jiménez, Morgane Wartel, Mara Stadler, André Mateus, Christian Müller, Ana Rita Brochado

    In Gram-negative bacteria, the uptake and export of a wide range of molecules, including antibiotics, is facilitated by porins and efflux pumps. Because of their role in regulating small molecule permeability of the outer and inner membrane, these transport machineries are tightly regulated at the transcriptional and post-transcriptional levels. However, regulation of transport by external chemical cues remains poorly understood. Here we investigated transcriptional regulation of three prominent transporter genes in Escherichia coli across 94 defined chemical cues, and simultaneously mapped the contributions of the key regulators MarA, SoxS and Rob to promoter activity. One third of all tested compounds triggered transcriptional changes, the majority of which were previously unknown. Importantly, we exposed main drivers of transport control in E. coli, e.g., bacteriostatic but not bactericidal antibiotics trigger the expression of efflux pumps, and Rob contributes to ~1/3 of all measured transcriptional changes, thereby emerging as a more prominent regulator of transport than previously thought. We showcase the potential of our resource by elucidating the molecular mechanism of antibiotic antagonisms with widely consumed caffeine in E. coli. Altogether, our analysis provides a quantitative overview of how different regulators orchestrate the transcriptional response of major transport determinants to environmental chemical cues.


  • Top Cited Papers
    Open Access

    Pre-trained molecular representations enable antimicrobial discovery

    by Roberto Olayo-Alarcon, Martin K. Amstalden, Annamaria Zannoni, Medina Bajramovic, Cynthia M. Sharma, Ana Rita Brochado, Mina Rezaei, Christian L. Müller

    The rise in antimicrobial resistance poses a worldwide threat, reducing the efficacy of common antibiotics. Determining the antimicrobial activity of new chemical compounds through experimental methods remains time-consuming and costly. While compound-centric deep learning models promise to accelerate this search and prioritization process, current strategies require large amounts of custom training data. Here, we introduce a lightweight computational strategy for antimicrobial discovery that builds on MolE (Molecular representation through redundancy reduced Embedding), a self-supervised deep learning framework that leverages unlabeled chemical structures to learn task-independent molecular representations. By combining MolE representation learning with available, experimentally validated compound-bacteria activity data, we design a general predictive model that enables assessing compounds with respect to their antimicrobial potential. Our model correctly identifies recent growth-inhibitory compounds that are structurally distinct from current antibiotics. Using this approach, we discover de novo, and experimentally confirm, three human-targeted drugs as growth inhibitors of Staphylococcus aureus. This framework offers a viable, cost-effective strategy to accelerate antibiotic discovery.


  • Open Access

    Statistical end-to-end analysis of large-scale microbial growth data with DGrowthR

    by Medina Feldl, Roberto Olayo-Alarcon, Martin K. Amstalden, Annamaria Zannoni, Stefanie Peschel, Cynthia M. Sharma, Ana Rita Brochado, Christian L. Müller

    Quantitative analysis of microbial growth curves is essential for understanding how bacterial populations respond to environmental cues. Traditional analysis approaches make parametric assumptions about the functional form of these curves, limiting their usefulness for studying conditions that distort standard growth curves. In addition, modern robotics platforms enable the high-throughput collection of large volumes of growth data, thus requiring strategies that can analyze large-scale growth data in a flexible and efficient manner. Here, we introduce DGrowthR , a statistical R framework and standalone app with a no-code interface for the integrative analysis of large growth experiments. DGrowthR comprises methods for data pre-processing and standardization, exploratory functional data analysis, and non-parametric modeling of growth curves using Gaussian Process regression. Importantly, DGrowthR includes a rigorous statistical testing framework for differential growth (DG) analysis. To illustrate the range of application scenarios of DGrowthR , we analyzed three large-scale bacterial growth datasets targeting distinct scientific inquiries. On an in-house dataset comprising more than 20, 000 growth curves of two pathogens that were subjected to chemical perturbations, DGrowthR enabled the discovery of compounds with significant growth inhibitory effects as well as compounds that induce non-canonical growth dynamics. On two publicly available perturbation datasets (> 100, 000 growth curves), DG analysis recovered reported adjuvants and antagonists of antibiotic activity, as well as bacterial genetic factors that determine susceptibility to specific antibiotic treatments. We anticipate DGrowthR to streamline the analysis of high-volume growth experiments, enabling researchers to make biological discoveries in a standardized and reproducible manner.


  • Open Access

    Systematic Characterization of Transport Regulation in Escherichia coli across defined environmental cues

    by Christoph Binsfeld, Roberto Olayo Alarcon, Morgane Wartel, Mara Stadler, Christian Müller, Ana Rita Brochado

    Transport of small molecules across the bacterial cell envelope is essential to ensure nutrient uptake and protect bacteria from toxic compounds. Due to its decisive role, transport is controlled by complex regulatory networks, knowledge of which – in particular across external cues – remains poorly understood. Here we investigate transcriptional regulation of seven prominent transport genes in Escherichia coli across 94 defined chemical cues, and simultaneously map the contributions of the key regulators MarA, SoxS and Rob to promoter activity. One third of all tested compounds triggered transcriptional changes, the vast majority of which previously unknown. Importantly, we exposed main drivers of transport control in E. coli , e.g. bacteriostatic, but not bactericidal, antibiotics trigger expression of efflux pumps, and that Rob contributes to ∼1/3 of all measured transcriptional changes, thereby emerging as a more prominent transport regulator than previously thought. We showcase the potential of our resource by elucidating the molecular mechanism of antibiotic antagonisms with widely consumed caffeine in E. coli . Altogether, our resource capitalizes on providing a quantitative overview of transport determinants across environments, and brings perspective to long-term prevailing concepts in the field.

  • The Vibrio cholerae CBASS phage defence system modulates resistance and killing by antifolate antibiotics

    by Susanne Brenzinger, Martina Airoldi, Adewale Joseph Ogunleye, Karl Jugovic, Martin Krähenbühl Amstalden, Ana Rita Brochado

    Toxic bacterial modules such as toxin–antitoxin systems hold antimicrobial potential, though successful applications are rare. Here we show that in Vibrio cholerae the cyclic-oligonucleotide-based anti-phage signalling system (CBASS), another example of a toxic module, increases sensitivity to antifolate antibiotics up to 10×, interferes with their synergy and ultimately enables bacterial lysis by these otherwise classic bacteriostatic antibiotics. Cyclic-oligonucleotide production by the CBASS nucleotidyltransferase DncV upon antifolate treatment confirms full CBASS activation under these conditions, and suggests that antifolates release DncV allosteric inhibition by folates. Consequently, the CBASS–antifolate interaction is specific to CBASS systems with closely related nucleotidyltransferases and similar folate-binding pockets. Last, antifolate resistance genes abolish the CBASS–antifolate interaction by bypassing the effects of on-target antifolate activity, thereby creating potential for their coevolution with CBASS. Altogether, our findings illustrate how toxic modules can impact antibiotic activity and ultimately confer bactericidal activity to classical bacteriostatic antibiotics.


  • Open Access

    Systematic analysis of drug combinations against Gram-positive bacteria

    by Elisabetta Cacace, Vladislav Kim, Vallo Varik, Michael Knopp, Manuela Tietgen, Amber Brauer-Nikonow, Kemal Inecik, André Mateus, Alessio Milanese, Marita Torrissen Mårli, et al.

    Drug combinations can expand options for antibacterial therapies but have not been systematically tested in Gram-positive species. We profiled ~8,000 combinations of 65 antibacterial drugs against the model species Bacillus subtilis and two prominent pathogens, Staphylococcus aureus and Streptococcus pneumoniae. Thereby, we recapitulated previously known drug interactions, but also identified ten times more novel interactions in the pathogen S. aureus, including 150 synergies. We showed that two synergies were equally effective against multidrug-resistant S. aureus clinical isolates in vitro and in vivo. Interactions were largely species-specific and synergies were distinct from those of Gram-negative species, owing to cell surface and drug uptake differences. We also tested 2,728 combinations of 44 commonly prescribed non-antibiotic drugs with 62 drugs with antibacterial activity against S. aureus and identified numerous antagonisms that might compromise the efficacy of antimicrobial therapies. We identified even more synergies and showed that the anti-aggregant ticagrelor synergized with cationic antibiotics by modifying the surface charge of S. aureus. All data can be browsed in an interactive interface (https://apps.embl.de/combact/).


  • Open Access

    The antiphage defense system CBASS controls resistance and enables killing by antifolate antibiotics in Vibrio cholerae

    by Susanne Brenzinger, Martina Airoldi, Adewale Joseph Ogunleye, Ana Rita Brochado

    Summary: Toxic bacterial modules, in particular toxin-antitoxin (TA) systems, have been long sought-after for their antimicrobial potential, although with limited success 1–6 . Here we show that the cyclic-oligonucleotide-based antiphage signaling system (CBASS), another example of a toxic module, increases sensitivity to well-established antifolate antibiotics, interferes with their synergy, and ultimately enables bacterial lysis by antifolates - classic bacteriostatic antibiotics, in Vibrio cholerae . We propose a molecular mechanism for the CBASS-antifolate interaction based on onset of cyclic-oligonucleotide production by the nucleotidyltransferase DncV upon folate depletion by antifolates. CBASS-antifolate interaction is specific to CBASS systems with closely related nucleotidyltransferases and similar folate binding. Altogether, our findings illustrate that toxic modules, such as the antiphage defense CBASS system, can dramatically impact antibiotic activity, and open the possibility that endogenous metabolites could also act as triggers/silencers of toxic modules under stress beyond antibiotic treatment, such as during phage infection, biofilm formation or disease environments.


  • Open Access

    High-throughput profiling of drug interactions in Gram-positive bacteria

    by Elisabetta Cacace, Vladislav Kim, Michael Knopp, Manuela Tietgen, Amber Brauer-Nikonow, Kemal Inecik, André Mateus, Alessio Milanese, Marita Torrissen Mårli, Karin Mitosch, et al.

    Drug combinations present a powerful strategy to tackle antimicrobial resistance, but have not been systematically tested in many bacterial species. Here, we used an automated high-throughput setup to profile ∼ 8000 combinations between 65 antibacterial drugs in three Gram-positive species: the model species, Bacillus subtilis and two prominent pathogens, Staphylococcus aureus and Streptococcus pneumoniae . Thereby, we recapitulate previously known drug interactions, but also identify ten times more interactions than previously reported in the pathogen S. aureus , including two synergies that were also effective in multi-drug resistant clinical S. aureus isolates in vitro and in vivo . Interactions were largely species-specific and mostly synergistic for drugs targeting the same cellular process, as observed also for Gram-negative species 1 . Yet, the dominating synergies are clearly distinct between Gram-negative and Gram-positive species, and are driven by different bottlenecks in drug uptake and vulnerabilities of their cell surface structures. To further explore interactions of commonly prescribed non-antibiotic drugs with antibiotics, we tested 2728 of such combinations in S. aureus , detecting a plethora of unexpected antagonisms that could compromise the efficacy of antimicrobial treatments in the age of polypharmacy. We uncovered even more synergies than antagonisms, some of which we could demonstrate as effective combinations in vivo against multi-drug resistant clinical isolates. Among them, we showed that the antiaggregant ticagrelor interferes with purine metabolism and changes the surface charge of S. aureus, leading to strong synergies with cationic antibiotics. Overall, this exemplifies the untapped potential of approved non-antibacterial drugs to be repurposed as antibiotic adjuvants. All data can be browsed through an interactive interface ( https://apps.embl.de/combact/ ).